Fortunately, there are multiple drugs being investigated for this condition. One is Viaskin, created by DBV Technologies ( DBVT 4.25% ), which functions as an applied skin-patch that gradually increases the amount of tolerance for peanut protein in children with the allergy. The drug, however, is far from perfect and has to overcome severe hurdles before it has a shot at regulatory approval. Aimmune Therapeutics ( AIMT ) is another biotech with an innovative treatment aimed at helping children with peanut allergy. Without further ado, let's investigate these potentially cutting edge treatments to see if either biotech stock is a buy.